Stifel reiterates Buy rating on Soleno Therapeutics stock at $118 target
PositiveFinancial Markets

Stifel has reaffirmed its Buy rating on Soleno Therapeutics, setting a target price of $118 for the stock. This endorsement reflects confidence in the company's potential for growth and success in the market, which is encouraging news for investors looking for promising opportunities in the biotech sector.
— Curated by the World Pulse Now AI Editorial System